Moderna, Inc. is a clinical-stage pharmaceutical company, primarily focused on discovering and developing messenger RNA (mRNA) based therapies. The company's mRNA based COVID-19 vaccine, Spikevax (mRNA-1273), is approved for use in adults in the United States. The vaccine is also authorized for emergency use in several countries as COVID-19 vaccine. The company has also developed booster doses of its COVID-19 vaccine and is developing variant-specific booster candidates.
Revenue (Most Recent Fiscal Year) | $3.24B |
Net Income (Most Recent Fiscal Year) | $-3.56B |
PE Ratio (Current Year Earnings Estimate) | -- |
PE Ratio (Trailing 12 Months) | -- |
PEG Ratio (Long Term Growth Estimate) | -- |
Price to Sales Ratio (Trailing 12 Months) | 3.25 |
Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 1.02 |
Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
Pre-Tax Margin (Trailing 12 Months) | -107.21% |
Net Margin (Trailing 12 Months) | -105.67% |
Return on Equity (Trailing 12 Months) | -28.69% |
Return on Assets (Trailing 12 Months) | -21.94% |
Current Ratio (Most Recent Fiscal Quarter) | 4.22 |
Quick Ratio (Most Recent Fiscal Quarter) | 4.14 |
Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
Inventory Turnover (Trailing 12 Months) | 5.52 |
Book Value per Share (Most Recent Fiscal Quarter) | $28.33 |
Earnings per Share (Most Recent Fiscal Quarter) | $-2.52 |
Earnings per Share (Most Recent Fiscal Year) | $-8.87 |
Diluted Earnings per Share (Trailing 12 Months) | $-8.73 |
Exchange | NASDAQ |
Sector | Healthcare |
Industry | Biotechnology |
Common Shares Outstanding | 386.74M |
Free Float | 344.20M |
Market Capitalization | $10.31B |
Average Volume (Last 20 Days) | 12.43M |
Beta (Past 60 Months) | 1.86 |
Percentage Held By Insiders (Latest Annual Proxy Report) | 11.00% |
Percentage Held By Institutions (Latest 13F Reports) | 75.33% |
Annual Dividend (Based on Last Quarter) | $0.00 |
Dividend Yield (Based on Last Quarter) | 0.00% |